These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 22923165

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 4. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL.
    Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
    [Abstract] [Full Text] [Related]

  • 5. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S, Saif MW.
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [Abstract] [Full Text] [Related]

  • 9. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J, Tabernero J.
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP.
    J Med Econ; 2012 Aug; 15 Suppl 1():55-64. PubMed ID: 22881362
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S.
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [Abstract] [Full Text] [Related]

  • 12. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T, Roukos DH.
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S, Gress TM, Michl P, Rinke A.
    Digestion; 2017 Sep; 96(2):67-75. PubMed ID: 28728148
    [Abstract] [Full Text] [Related]

  • 15. Recent studies show promise for treating rare pancreatic tumors.
    Peres J.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):624-7. PubMed ID: 21474831
    [No Abstract] [Full Text] [Related]

  • 16. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
    Benavent M, de Miguel MJ, Garcia-Carbonero R.
    Target Oncol; 2012 Jun 20; 7(2):99-106. PubMed ID: 22585431
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE, Sherman SK, Howe JR.
    Clin Cancer Res; 2016 Oct 15; 22(20):5022-5029. PubMed ID: 27742788
    [Abstract] [Full Text] [Related]

  • 19. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F, Visvardis EE, Sita-Lumsden A, Waxman J.
    QJM; 2012 Sep 15; 105(9):819-22. PubMed ID: 22383691
    [Abstract] [Full Text] [Related]

  • 20. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N, IEO ENETS Center of Excellence for GEP NETs.
    Target Oncol; 2017 Oct 15; 12(5):611-622. PubMed ID: 28634872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.